Prognostic Study of Via Dynamic Change of dT-DNA in Drainage Fluid After Radical Prostatectomy
Prognostic Study of Prostate Cancer Via Dynamic Change of Drainage Tumor DNA(dT-DNA) in Peritoneal Drainage Fluid After Radical Prostatectomy
1 other identifier
observational
100
1 country
1
Brief Summary
This study investigates the prognostic value of dynamic changes in Drainage Tumor DNA(dT-DNA) levels found in the peritoneal drainage fluid after radical prostatectomy. Prostate cancer is one of the most common cancers in men, and radical prostatectomy is a standard treatment. While PSA levels in the blood are commonly used as a marker for diagnosis, this study focuses on the significance of dT-DNA levels in the prognosis of prostate cancer. The findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 21, 2024
CompletedFirst Posted
Study publicly available on registry
November 27, 2024
CompletedStudy Start
First participant enrolled
December 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedNovember 27, 2024
November 1, 2024
1 year
September 21, 2024
November 26, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
dT-DNA Levels in Drainage Fluid
Postoperative dT-DNA Levels in The Peritoneal Drainage Fluid
Measured daily for up to 3 days post-surgery
Eligibility Criteria
The study will include male patients diagnosed with prostate cancer who need radical prostatectomy. Participants must have a preoperative diagnosis confirmed by biopsy and imaging studies. Eligible patients will have an abdominal drainage system in place post-surgery for fluid collection.
You may qualify if:
- Prostate cancer patients treated with radical prostatectomy
You may not qualify if:
- \. Received neoadjuvant endocrine/chemotherapy before surgery;
- \. Urine leakage after surgery (positive creatinine test of drainage fluid).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080, China
Biospecimen
In this study, biospecimens consist of peritoneal drainage fluid of patients following radical prostatectomy. The fluid is obtained through standard post operative drainage procedures. The collected samples are analyzed to measure the levels of dT-DNA over a designated post-surgical period. The dT-DNA levels in the drainage fluid are dynamically monitored and recorded to assess potential correlations with patient outcomes, recurrence, and metastasis.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Huaqi Zhan
https://www.shgh.cn/home/index.html
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 21, 2024
First Posted
November 27, 2024
Study Start
December 1, 2024
Primary Completion
December 1, 2025
Study Completion
December 1, 2025
Last Updated
November 27, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share